Non-myeloablative hematopoietic stem cell transplantation.
Maris M, Sandmaier BM, Maloney DG, McSweeney PA, Woolfrey A, Chauncey T, Shizuru J, Niederwieser D, Blume KG, Forman S, Storb R.
Transfus Clin Biol. 2001 Jun;8(3):231-4. doi: 10.1016/s1246-7820(01)00137-9.
Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management.
Ansell SM.
Am J Hematol. 2024 Dec;99(12):2367-2378. doi: 10.1002/ajh.27470. Epub 2024 Sep 6.
Non-myeloablative transplantation.
Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA.
Hematology Am Soc Hematol Educ Program. 2002:392-421. doi: 10.1182/asheducation-2002.1.392.
How we treat primary central nervous system lymphoma.
Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM.
ESMO Open. 2021 Aug;6(4):100213. doi: 10.1016/j.esmoop.2021.100213. Epub 2021 Jul 13.
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas.
Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM.
Leuk Lymphoma. 2022 Jan;63(1):231-234. doi: 10.1080/10428194.2021.1975190. Epub 2021 Sep 6.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Lykke Petersen S, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hübel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg JH, Scott BL, McDonald GB, Storb R, Sandmaier BM.
Haematologica. 2021 Jun 1;106(6):1599-1607. doi: 10.3324/haematol.2020.248187.
Stem cell transplantation for systemic sclerosis.
Bruera S, Sidanmat H, Molony DA, Mayes MD, Suarez-Almazor ME, Krause K, Lopez-Olivo MA.
Cochrane Database Syst Rev. 2022 Jul 29;7(7):CD011819. doi: 10.1002/14651858.CD011819.pub2.
A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.
Atilla E, Ataca Atilla P, Demirer T.
Balkan Med J. 2017 Jan;34(1):1-9. doi: 10.4274/balkanmedj.2017.0055. Epub 2017 Jan 5.
Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation.
Gjærde LK, Ostrowski SR, Jørgensen NR, Schierbeck F, Andersen NS, Friis LS, Kornblit B, Petersen SL, Schjødt I, Sengeløv H.
Transpl Immunol. 2022 Oct;74:101650. doi: 10.1016/j.trim.2022.101650. Epub 2022 Jun 16.
The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span.
Rožman P.
Geroscience. 2018 Jun;40(3):221-242. doi: 10.1007/s11357-018-0027-x. Epub 2018 Jun 14.
